No Data
No Data
No Data
No Data
No Data
89bio Coverage Assumed by B of A Securities at Buy
89bio Coverage Assumed by B of A Securities at Buy
Dow JonesApr 22 18:24
B of A Securities Assumes 89bio at Buy, Announces Price Target of $30
B of A Securities analyst Alexandria Hammond assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $30.
BenzingaApr 22 18:14
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 20 05:10
89bio Enhances Board With Biopharma Veteran Martin Babler
TipRanksApr 18 04:22
89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
89bio, Inc. (Nasdaq: ETNB) today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024.
GlobeNewswireApr 18 04:05
89bio Signs Deal for Construction of a Production Facility in China
Seeking AlphaApr 11 05:14
No Data
No Data